{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125933","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.720706+00:00","generated_at":"2026-05-30T00:53:50.937372+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CalciMedica reports Q3 net loss $5.6M, completes $10.2M offering; cash runway into H1 2026","bullets":["Q3 2024 net loss $5.6M ($0.50/sh); total loss from operations $5.7M.","Cash $14.6M at Sep 30; pro forma after Oct offering ~$23.7M, funds ops into H1 2026.","Completed Nov 1 public offering: 2.72M shares at $3.75, gross proceeds $10.2M.","Phase 2b CARPO: win ratio 1.64 (p=0.0372) for high-dose Auxora vs placebo; 100% relative risk reduction in new-onset severe respiratory failure.","Expects Phase 3 start in 2025; topline data from KOURAGE (AKI) and CRSPA (AIPT) trials in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125933","json":"https://secwatch.observer/filing/0000950170-24-125933.json","markdown":"https://secwatch.observer/filing/0000950170-24-125933.md","text":"https://secwatch.observer/filing/0000950170-24-125933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/0000950170-24-125933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:53:50.937372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}